Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.46 |
| ▸ | WNT3A | P56704 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071493 | 0.93 | HPGDS (0.55) | HPGDSPAK1WNT3AMAP4K4ENPP1 | |
| SCHEMBL2072061 | 0.85 | HPGDS (0.57) | HPGDSPAK1 | |
| SCHEMBL2073544 | 0.83 | HPGDS (0.62) | HPGDSPAK1MAP4K4GRM5USP30 | |
| SCHEMBL2072275 | 0.83 | HPGDS (0.57) | HPGDSPAK1WNT3AENPP1ALDH1A1 | |
| SCHEMBL2071494 | 0.82 | HPGDS (0.53) | HPGDSWNT3AMAP4K4ALDH1A1GABRA5 | |
| SCHEMBL2071670 | 0.81 | HPGDS (0.61) | HPGDSPAK1JAK2JAK3 | |
| SCHEMBL2072769 | 0.81 | HPGDS (0.57) | HPGDSWNT3AALDH1A1GABRA5GRM5 | |
| SCHEMBL2072474 | 0.80 | HPGDS (0.60) | HPGDSPAK1MAP4K4GRM5USP30 | |
| SCHEMBL2071086 | 0.80 | PAK1 (0.71) | HPGDSPAK1 | |
| SCHEMBL2070217 | 0.80 | HPGDS (0.57) | HPGDSPAK1MAP4K4ALDH1A1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885PAK1 1200/4885WNT3A 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.